Gunderson Dettmer represented Pipeline Therapeutics on the deal. Pipeline Therapeutics, a clinical-stage biopharmaceutical company, entered into a global license and development agreement with Janssen Pharmaceutica NV...
Pipeline Therapeutics’ Global License and Development Agreement with Janssen
Replicate Biosciences’ Licensing Agreement with Precision NanoSystems
Gunderson Dettmer advised Replicate Bioscience on the deal. Replicate Bioscience, a San Diego-based biotechnology company, announced its licensing agreement to collaborate with Precision NanoSystems, a developer of...
Brightseed’s $68 Million Series B Financing
Gunderson Dettmer represented Brightseed on the deal. Brightseed, a San Francisco-based developer of plant nutrient technology, announced its $68 million Series B financing led by Temasek. Brightseed...
Xencor’s $100 Million Collaboration Agreement with Johnson & Johnson
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Xencor on the deal. Xencor, a clinical-stage biopharmaceutical company, announced its $100 million collaboration agreement with Johnson &...
Tarsus Pharmaceuticals’ Strategic Partnership with LianBio
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Tarsus Pharmaceuticals, Inc. on the deal. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and...